Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Major biomarker candidates for Alzheimer’s disease explored: holds promise for improving the diagnosis and ...

08.03.2006


... Management of Dementia



Alzheimer’s disease--specific biomarkers clearly are needed for the differential diagnosis of cognitive impairment in the elderly. What sets age-related disorders like hypertension, hypercholesterolemia and diabetes mellitus apart from Alzheimer’s disease is that each has biomarkers that can be followed easily and repeatedly, not simply to diagnose, but also to monitor response and optimize treatment. In contrast, the current role of clinical laboratory evaluation for dementia is exclusionary. The development of such biomarkers is critical to translating efficiently the new therapeutic approaches for AD under development by many research groups into treatments for the millions who suffer from AD.

The March issue of the Journal of Alzheimer’s Disease (www.j-alz.com) published by IOS Press is devoted to the current research into "Biomarkers for Alzheimer’s Disease.” In the foreword by Elaine R. Peskind and guest editor Thomas J. Montine (University of Washington), the challenges and limitations of our current knowledge of AD biomarkers are outlined. These investigators emphasize that "Progress toward controlling if not eradicating AD is at a crossroads where clinical, pathological and basic science studies have identified therapeutic targets that are now being tested. Critical to translating this knowledge to improved patient care will be developing panels of biomarkers that complement the clinical exam, cognitive testing, and neuroimaging." In six articles, prominent researchers and clinicians involved in AD studies review the search for potential biomarkers for this debilitating disease.


Jeffrey L. Cummings (University of California at Los Angeles) discusses the use of clinical evaluation as a biomarker for AD, pointing out the need for biomarkers that accurately reflect clinical outcomes.

Following this theme, Douglas Galasko (University of California at San Diego) reviews some of the current candidates for AD biomarkers, such as amyloid-beta, tau, and phospho-tau. Other biomarkers that target inflammatory and oxidative damage processes may have future potential.

In a disease with no known cure and no treatments that can delay onset or prevent progression, prediction of future pathology is particularly important. In “The search for antecedent biomarkers of Alzheimer’s disease,” Anne M. Fagan, Cynthia A. Csernansky, John C. Morris, and David M. Holtzman (Washington University in St. Louis), discuss some of the challenges surrounding the development of biomarkers for “preclinical AD.”

Thomas J. Montine, Joseph F. Quinn, Kathleen S. Montine, Jeffrey A. Kaye, and John C.S. Breitner (University of Washington and Oregon Health & Science University), in “Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer’s disease,” discuss how the monitoring of F2-isoprostanes in cerebro-spinal fluid (CSF) is showing promise as a diagnostic tool for monitoring potential anti-oxidant therapies for AD.

Inflammatory processes have also been implicated in AD. Robert E. Mrak and W. Sue T. Griffin (University of Arkansas) review proinflammatory cytokines as potential markers for AD, pointing out in “Inflammatory biomarkers in Alzheimer’s disease” the difficulties in the use of such markers due to complicating genetic factors.

Finally, Jing Zhang, David R. Goodlett, and Thomas J. Montine (University of Washington) discuss recent advances in genomics, proteomics, and metabolomics. In “Proteomic Biomarker Discovery in Cerebrospinal Fluid for Neurodegenerative Diseases,” the prospect for clinical diagnosis via unique protein markers is reviewed, as well as the practical limitations of proteomic analysis of human CSF.

In addition to the articles, the issue features transcripts of two live panel discussions of the Alzheimer Research Forum, “Imaging in Alzheimer’s Disease: The Current State of Affairs” and “Making a BioMark on Alzheimer Disease.” (The Alzheimer Research Forum, founded in 1996, is the web’s most dynamic scientific community dedicated to understanding Alzheimer’s disease and related disorders.)

Astrid Engelen | alfa
Further information:
http://www.j-alz.com

More articles from Life Sciences:

nachricht Microscope measures muscle weakness
16.11.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

nachricht Good preparation is half the digestion
16.11.2018 | Max-Planck-Institut für Stoffwechselforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

Purdue cancer identity technology makes it easier to find a tumor's 'address'

16.11.2018 | Health and Medicine

Good preparation is half the digestion

16.11.2018 | Life Sciences

Microscope measures muscle weakness

16.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>